Listed

Tenaya Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2024

Filed with the SEC on May 14, 2024 and accepted by EDGAR at May 14, 2024, 20:15 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2024-01-01 to 2024-03-31$25.1mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2024-01-01 to 2024-03-31−$33.8mus-gaap:OperatingIncomeLoss
Income tax3 months2024-01-01 to 2024-03-31$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2024-01-01 to 2024-03-31−$32.2mus-gaap:NetIncomeLoss
Diluted EPS3 months2024-01-01 to 2024-03-31−$0.40us-gaap:EarningsPerShareDiluted
Basic EPS3 months2024-01-01 to 2024-03-31−$0.40us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2024-01-01 to 2024-03-3180,982,326 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2024-01-01 to 2024-03-31−$28.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2024-01-01 to 2024-03-31$564.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2024-03-31$59.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2024-03-31$128.7mus-gaap:AssetsCurrent
Total assetsAt period end2024-03-31$184.9mus-gaap:Assets
Current liabilitiesAt period end2024-03-31$19.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2024-03-31$26.7mus-gaap:Liabilities
Shareholders' equityAt period end2024-03-31$158.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-24-059576. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.